Kardigan
(Incorporated in Delaware) We are a Phase 2B/Phase 3 biotech advancing three late-stage cardiovascular therapies in indications for which no approved therapies currently exist: *Danicamtiv – An investigational oral cardiac atrial and ventricular myosin activator to treat genetic dilated cardiomyopathy (“DCM”) caused by pathogenic variants in myosin heavy chain 7 (“MYH7”) and titin (“TTN”), the […]
May 27, 2026 Read More